GemOx-R regimen
WikiDoc Resources for GemOx-R regimen |
Articles |
---|
Most recent articles on GemOx-R regimen Most cited articles on GemOx-R regimen |
Media |
Powerpoint slides on GemOx-R regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on GemOx-R regimen at Clinical Trials.gov Trial results on GemOx-R regimen Clinical Trials on GemOx-R regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on GemOx-R regimen NICE Guidance on GemOx-R regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on GemOx-R regimen Discussion groups on GemOx-R regimen Patient Handouts on GemOx-R regimen Directions to Hospitals Treating GemOx-R regimen Risk calculators and risk factors for GemOx-R regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for GemOx-R regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
GemOx-R regimen refers to a regimen consisting of rituximab, gemcitabine and oxaliplatin used to treat refractory and relapsing mantle cell lymphoma.[1]
Regimen
GemGemcitabine
OxOxaliplatin
RRituximab
Indications
- Refractory and relapsing mantle cell lymphoma.[1]
References
- ↑ 1.0 1.1 Rodríguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcón J; et al. (2007). "Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma". Leuk Lymphoma. 48 (11): 2172–8. doi:10.1080/10428190701618268. PMID 17990179.